Background: Lurbinectedin is a book anticancer agent currently undergoing late-stage (Stage II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breasts and small-cell lung tumor. direct aftereffect of lurbinectedin in the tumour microenviroment. in mouse tumour versions and in treated sufferers, and most likely constitute a significant determinant of its antitumour efficiency (Germano studies Individual monocytes… Continue reading Background: Lurbinectedin is a book anticancer agent currently undergoing late-stage (Stage